AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2021
Feb 16, 2021
30849_dirs_2021-02-16_b66042ba-34e2-4045-ac2e-414fd19c90f0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2021-02-11
Reporting Person: Kelner Simon (Chief Human Resources Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-11 | Restricted Stock Units | $ | A | 6250 | Acquired | Common Stock (6250) | Direct | |
| 2021-02-11 | Stock Option (Right to Buy) | $30.66 | A | 37500 | Acquired | 2031-02-10 | Common Stock (37500) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date
F3: The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.